# Study to Evaluate Palifermin in the Reduction of Dysphagia in Patients With Locally Advanced Non-Small Cell Lung Cancer (NSCLC)

> **NCT00094861** · PHASE2 · COMPLETED · sponsor: **Swedish Orphan Biovitrum** · enrollment: 100 (actual)

## Conditions studied

- Dysphagia
- Non-Small Cell Lung Cancer
- Lung Cancer

## Interventions

- **DRUG:** Palifermin
- **DRUG:** Placebo
- **RADIATION:** Radiotherapy
- **DRUG:** Paclitaxel
- **DRUG:** Carboplatin

## Key facts

- **NCT ID:** NCT00094861
- **Lead sponsor:** Swedish Orphan Biovitrum
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-01
- **Primary completion:** 2007-12
- **Final completion:** 2014-01
- **Target enrollment:** 100 (ACTUAL)
- **Last updated:** 2017-03-14

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00094861

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00094861, "Study to Evaluate Palifermin in the Reduction of Dysphagia in Patients With Locally Advanced Non-Small Cell Lung Cancer (NSCLC)". Retrieved via AI Analytics 2026-07-02 from https://api.ai-analytics.org/clinical/NCT00094861. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*